[DOI] [PMC free article] [PubMed] [Google Scholar] 2
Innovent Biologics dual GCG/GLP-1R has met its primary endpoint in the head-to-head Phase III DREAMS-3 study, & outperformed Novo Nordisks Semaglutide in a late-stage, in type 2 diabetes (T2D) patients with comorbid obesity
Its job is anti-inflammatory
The SELECT trial with semaglutide 2.4 mg demonstrated a 20% reduction in MACE among patients with established cardiovascular disease and overweight or obesity, even in those without diabetes
A missed dose may: Disrupt the hormonal balance your body was adapting to Delay or alter your menstrual cycle May worsen cycle issues after weight loss or low calorie intake Its also worth noting that some women experience temporary cycle changes just from being on GLP-1 therapy, even if they havent missed a dose
Finan B, Yang B, Ottaway N et al (2012) Targeted estrogen delivery reverses the metabolic syndrome